Former Eagle great Ron Jaworski signs on as Stopain spokesman
HAZELTON, Pa. — Troy Healthcare on Monday announced that Ron Jaworski, former Philadelphia Eagles quarterback and current “ESPN Football” analyst, has signed on to become a national spokesman for its Stopain line of topical analgesics.
“Ron is one of the most popular and respected athletes in Philadelphia sports history,” stated Thomas Cicini, president and CEO of Troy Healthcare. “His unquestioned loyalty, 10-year career with the Eagles and longstanding dedication to giving back to the community makes him the perfect fit for Stopain, and we’re thrilled that he joined the Stopain team as a [spokesman] on a national level.”
“I am very captivated by the Stopain team; their products are geared toward any age group or athlete,” Jaworski said. “I’ve tried many products to help with my arthritis pain as a result [of] years of playing football, but most only subside the pain. Stopain actually stops the pain; it’s terrific. Believe me, they are the ‘real deal.’"
NBTY acquires Balance Bar from private equity firm
GREENWICH, Conn. — Brynwood Partners VI on Monday announced that it has sold its Balance Bar Company, which manufactures nutrition and energy bars, to NBTY.
The value of the deal was not disclosed, though the Wall Street Journal reported that NBTY agreed to pay about $78 million for Balance Bar, citing people familiar with the transaction. According to that report, Balance Bars enjoy significant distribution across supermarkets, giving NBTY an opportunity to expand distribution through the convenience store and drug store channels.
Balance Bar was acquired by Brynwood in 2009 from Kraft Foods. The company, which is headquartered in Valhalla, N.Y., posted $26.6 million in sales of Balance bars across food, drug and mass (minus Walmart) for the 52 weeks ended Sept. 9, according to SymphonyIRI Group data. Sales for the period were up 4.7%, and the brand ranked No. 11 in SymphonyIRI’s nutritional/instrinsic health value bars. The category leader is General Mills Fiber One followed by Clif and Zone Perfect.
Reckitt Benckiser pursuit of Schiff Nutrition a success; companies sign definitive merger agreement
SLOUGH, England — Reckitt Benckiser successfully wrapped up its pursuit of Schiff Nutrition on Friday with the signing of a definitive merger agreement in a deal valued at $1.4 billion. Bayer officially relinquished its proposed acquisition on the same day.
“We are very pleased to have reached a mutually beneficial agreement with Schiff and are excited to enter the $30 billion global vitamins, minerals and supplements market with such a strong portfolio of high-quality branded business in the USA," stated Rakesh Kapoor, Reckitt Benckiser CEO. "Schiff’s portfolio is an excellent fit with our strategic focus on health and hygiene, where in health care in the [United States] we already have Mucinex, Delsym, Cepacol and Durex as major brands.”
Reckitt Benckiser expects the tender offer to close before the end of calendar year 2012.
"Bayer continues to believe that the transaction would have represented a logical and strategic addition for its Consumer Care business," the company stated in a press release issued Friday. "However, [Bayer] came to the conclusion that entering into a competitive bidding process would have resulted in a transaction price outside Bayer’s set financial criteria."
Bayer received a breakup fee of $22 million from Schiff, per the initial merger agreement between those two companies.